ROTTERDAM, Netherlands—Parx Plastics is broadening the scope of the antimicrobial technology it developed, patented and markets for plastic materials.
The company has set its sights on the burgeoning silicone market with a separate entity, Siliarity N.V. First established in 2017, Siliarity will manage and market bio-based technologies for silicone materials, starting with antimicrobial technologies based on or derived from the Parx Plastics patents and knowhow.
With the antimicrobial technology for liquid silicone rubber progressing toward an industrial scale, Parx Plastics has acquired a majority of the shares in Siliarity through a restructuring of the share capital. Testing is being carried out in collaboration with a major manufacturer of silicone products, who is also a co-investor, Parx Plastics said.
Parx Plastics' technology is based on a biomimetic approach: The technology uses a biocompatible trace element that in skin acts as the defense mechanism against microbes. It is a mechanism that is mimicked in plastics and polymers. By preventing bacteria and biofilm adhesion and proliferation, a reduction in the microbial load of 99.9 percent, measured according to ISO 22196, is achieved.
With the global LSR market projected to reach $3.82 billion by 2026, and with annual growth of 8.3 percent, it is a market presenting excellent prospects. Typical applications for LSR are products that require high precision such as seals and sealing membranes; infant products where smooth surfaces are desired, such as bottle nipples, medical applications as well as kitchen goods such as baking pans, spatulas, etc.—all applications where antimicrobial properties represent added value and additional safety for the end product.
Testing of the new antimicrobial-enhanced LSR is expected to continue throughout the remainder of 2019. The launch of the material is expected soon after, Parx Plastics said.